BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33517271)

  • 1. YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation.
    Kim HJ; Heo K
    Anticancer Res; 2021 Feb; 41(2):671-678. PubMed ID: 33517271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical development of a humanized neutralizing antibody targeting HGF.
    Kim H; Hong SH; Kim JY; Kim IC; Park YW; Lee SJ; Song SW; Kim JJ; Park G; Kim TM; Kim YH; Park JB; Chung J; Kim IH
    Exp Mol Med; 2017 Mar; 49(3):e309. PubMed ID: 28336956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression.
    Kim HJ; Lee S; Oh YS; Chang HK; Kim YS; Hong SH; Kim JY; Park YW; Lee SJ; Song SW; Kim JJ; Heo K
    Front Oncol; 2019; 9():571. PubMed ID: 31355133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
    Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
    Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
    Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
    Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV
    Br J Cancer; 2016 Feb; 114(3):269-80. PubMed ID: 26766740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of tumor growth in a mouse xenograft model by the humanized anti-HGF monoclonal antibody YYB-101 produced in a large-scale CHO cell culture.
    Song SW; Lee SJ; Kim CY; Song JK; Jung EJ; Choi YB; Min SW; Oh JW
    J Microbiol Biotechnol; 2013 Sep; 23(9):1327-38. PubMed ID: 23851271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arborinine suppresses ovarian cancer development through inhibition of LSD1.
    Li N; Yang L; Zuo H
    Life Sci; 2022 Feb; 291():120275. PubMed ID: 34979197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma.
    Sa JK; Kim SH; Lee JK; Cho HJ; Shin YJ; Shin H; Koo H; Kim D; Lee M; Kang W; Hong SH; Kim JY; Park YW; Song SW; Lee SJ; Joo KM; Nam DH
    Neuro Oncol; 2019 Feb; 21(2):222-233. PubMed ID: 29939324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.
    Bu R; Uddin S; Bavi P; Hussain AR; Al-Dayel F; Ghourab S; Ahmed M; Al-Kuraya KS
    Lab Invest; 2011 Jan; 91(1):124-37. PubMed ID: 20661229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
    Liu L; Zeng W; Wortinger MA; Yan SB; Cornwell P; Peek VL; Stephens JR; Tetreault JW; Xia J; Manro JR; Credille KM; Ballard DW; Brown-Augsburger P; Wacheck V; Chow CK; Huang L; Wang Y; Denning I; Davies J; Tang Y; Vaillancourt P; Lu J
    Clin Cancer Res; 2014 Dec; 20(23):6059-70. PubMed ID: 25231402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Songorine suppresses cell growth and metastasis in epithelial ovarian cancer via the Bcl‑2/Bax and GSK3β/β‑catenin signaling pathways.
    Zhang H; Dong R; Zhang P; Wang Y
    Oncol Rep; 2019 May; 41(5):3069-3079. PubMed ID: 30896826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.
    Zillhardt M; Christensen JG; Lengyel E
    Neoplasia; 2010 Jan; 12(1):1-10. PubMed ID: 20072648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
    Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
    Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
    Chen L; Li C; Zhu Y
    Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
    Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
    Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
    Sun ZJ; Wu Y; Hou WH; Wang YX; Yuan QY; Wang HJ; Yu M
    Oncotarget; 2017 Apr; 8(17):29067-29079. PubMed ID: 28404966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
    Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.